HOME >> BIOLOGY >> NEWS
Role of cytokine inhibition in chronic heart failure

Tumor Necrosis Factor Receptor Topic of Plenary, Oral Sessions

SEATTLE, November 2, 1999- Researchers continue to explore an emerging approach in the study of heart failure, a disease that affects nearly five million Americans and contributes to more than 260,000 deaths each year. New research on the effect of inhibiting the inflammatory cytokine tumor necrosis factor (TNF) will be presented at the 72nd Scientific Sessions of the American Heart Association (AHA) from November 7-11 in Atlanta.

"Inhibiting proinflammatory cytokines that may contribute to the progression of heart failure represents a unique and exciting approach for research in heart failure," said Douglas Mann, MD, professor of medicine at Baylor College of Medicine and a pioneer in this area of study. "Our initial studies with ENBREL -- a soluble TNF receptor -- suggested that inhibiting TNF could improve the signs and symptoms of heart failure in patients with moderate heart failure, as well as improve some aspects of cardiac function in these patients."

    TO ARRANGE AN INTERVIEW WITH DR. MANN, PLEASE CALL PAM RABE OF IMMUNEX AT 206-470-4131 OR GINGER HALL OF MCS, INC., AT 800-477-9626.

During the Scientific Sessions, three presentations will feature the role of TNF in chronic heart failure (CHF). Two of the oral sessions will present new data on the use of ENBREL (Etanercept) in CHF. The role of TNF also will be featured at Plenary Session VI on Tuesday morning. Following are details of the sessions.

Suppression of Cardioinflammatory Cytokines by ENBREL (Etanercept, p75 TNF Receptor Fusion Protein) Correlates with Clinical Improvement in Heart Failure Patients - Abstract # 107774
Sunday, November 7, 4:00 pm
Location: Room 365/367W
Presenter: Biykem Bozkurt, MD, Baylor College of Medicine

Plenary Session VII: Research in Heart Failure: Implications for Future Treatment
Presentation: Inflammat
'"/>

Contact: Pam Rabe
prabe@immunex.com
206-470-4131
Immunex Corporation
9-Nov-1999


Page: 1 2

Related biology news :

1. Lowly cytokine may play role in controlling neurotransmitters
2. The RANKL cytokine at 2.6
3. FDA approves VYTORIN, first and only to powerfully reduce LDL cholesterol through dual inhibition
4. Genes appear to play a role in development of chronic obstructive pulmonary disease
5. New research supports theory that indirect transmission of chronic wasting disease
6. Animal studies show promise treating severe chronic pain
7. Researchers show chronic sinusitis is immune disorder; antifungal medicine effective treatment
8. HIV exhausts the immune system through chronic non-specific activation
9. Medical students inadequately prepared for clinical rotations, caring for chronically ill
10. FDA approves Raptiva (efalizumab) for chronic moderate-to-severe plaque psoriasis
11. NIH told regular and moderate exposure to sunlight is the key to preventing chronic disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... ... August 18, 2020 , ... Sentien ... announced that the U.S. Food and Drug Administration (FDA) has approved the company’s ... for the treatment of severe COVID-19. Approval of this IND allows Sentien to ...
(Date:8/12/2020)... ... August 11, 2020 , ... Both Roche, based ... entered into license agreements with Housey Pharma’s HMI subsidiary to gain access to ... have annual Research and Development spending in excess of US $10 billion. , ...
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval from ... and ProText™, making them the first Wharton’s jelly allografts to be assigned a Q ... company’s solutions are the first Wharton’s jelly allograft product to be recognized as a ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... 2020 , ... After research model surgery and catheter implantation, the long journey ... the beginning of a successful study, while protecting and accessing the catheter or device ... of Surgery from Envigo in a live webinar on Wednesday, ...
(Date:7/18/2020)... ... July 16, 2020 , ... Medial EarlySign , a ... prevention of high-burden diseases, and Centric Consulting, a business and technology consulting firm, ... existing data in order to identify and prioritize patients for care. , Combining ...
(Date:7/10/2020)... ... 2020 , ... Bode Technology, a leading provider ... through its COVID-19 testing service, Bode-CARES . Bode-CARES combines high-volume clinical testing ... provides a turnkey solution that includes a comprehensive collection and virus-management program for ...
(Date:7/10/2020)... HONG KONG (PRWEB) , ... July 09, 2020 ... ... chemical compound called 1-phenyl-2-thiourea (PTU) is commonly used to suppress pigment formation in ... years, the PolyU research team led by Dr MA has been using the ...
Breaking Biology Technology:
Cached News: